Jul 30, 2024 8:05am EDT Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update
Jun 24, 2024 4:05pm EDT Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application
Jun 03, 2024 8:13am EDT Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting
May 23, 2024 5:00pm EDT Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
May 07, 2024 4:01pm EDT Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
Apr 30, 2024 8:05am EDT Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update
Apr 04, 2024 8:05am EDT Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
